Medical Licensing (MD/DO) · Independent exam preparation
DNB Final Examination (Radiation Oncology) Study Guide
Practise target definition, radiobiology calculations, treatment selection and toxicity assessment for India’s postgraduate DNB Radiation Oncology exit examination.
By CertMedbry · Updated 18 October 2026
Build defensible treatment plans by connecting anatomy, radiation physics and tumour biology with staging, modality selection and toxicity management. Practise calculations, interpret imaging and trial results, and explain decisions in the structured language needed for written answers and clinical discussion. These 60 concepts selectively sample all eight curriculum domains; the official NBEMS curriculum remains the full scope. The guide follows the DNB trainee pathway through theory and practical assessment.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which qualification and candidate pathway does this guide address?
It addresses the DNB Final Examination in Radiation Oncology for registered DNB trainees taking theory followed by practical assessment in India. This is a postgraduate broad-specialty exit examination. The June 2026 bulletin also provides routes for post-diploma DNB trainees and eligible MD/MS-qualified candidates in the same specialty; their eligibility requirements differ. DrNB super-specialty examinations are conducted separately.
NBEMS Curriculum Index · DNB Final Examination June 2026 Information Bulletin
Why does the linked curriculum say Radio Therapy?
NBEMS currently lists the specialty as Radiation Oncology and links it to the undated curriculum titled DNB–Radio Therapy. The June 2026 bulletin documents historical Radio Therapy recognition from August 1982 and Radiation Oncology recognition from August 2020. These are recognition dates, not curriculum publication or effective dates.
NBEMS Curriculum Index · Guidelines for Competency Based Training Programme in DNB–Radio Therapy · DNB Final Examination June 2026 Information Bulletin
How many theory questions are there, and are pretest questions identified?
The June 2026 bulletin specifies four theory papers worth 100 marks each. Its general scheme gives 10 short notes of 10 marks per paper, while explicitly allowing the number and mark allocation to vary in some subjects or papers. Consequently, 40 short notes describes the general scheme rather than an unconditional Radiation Oncology item count. No separate scored/pretest question split is identified.
What duration, delivery and item styles are verified?
The June 2026 theory scheme permits three hours per paper and schedules examinations at designated centres. Theory generally uses short-note answers. Practical assessment comprises OSCE and/or clinical examination, and viva, with a maximum of 300 marks. A fixed practical duration and station count are not established here. Computer-adaptive delivery is not described. The 20 four-option questions in this guide are independent study drills.
What qualification thresholds does the verified bulletin state?
For June 2026, theory qualification requires at least 200/400 in aggregate. The bulletin specifies aggregate rounding and grace provisions for candidates scoring 192–199/400. Practical qualification requires at least 150/300, with aggregate rounding and no practical grace marks. These are session-specific rules; use the applicable NBEMS bulletin and corrigenda for a later sitting.
How does the practical-only variant relate to the full examination?
Practical-only participation is an examination-stage route for candidates with valid theory qualification and remaining permitted practical attempts. It is not a different Radiation Oncology qualification. The June 2026 scheme counts the practical examination immediately following theory qualification as the first attempt, whether attended or missed, and permits two further attempts within the next three consecutive sessions.
Which outline version and topic weights apply?
The official index and linked curriculum were checked on 18 October 2026. The linked curriculum states neither an edition nor an effective date, and no official topic percentages were established. The June 2026 bulletin filename identifies V1 dated 23 April 2026; that does not establish a new syllabus date. This guide allocates breadth educationally: 18 Basic Sciences, 18 Clinical Radiotherapy, eight Clinical Cancer Chemotherapy, four allied disciplines, four prevention, four palliation, two Training and two Administration concepts. Assessment marks are not topic weights.
NBEMS Curriculum Index · Guidelines for Competency Based Training Programme in DNB–Radio Therapy · DNB Final Examination June 2026 Information Bulletin
How should this selective guide be used alongside the official curriculum?
Use the official curriculum as the complete scope, including tumour sites, anatomy, pathology, emergencies, practical competencies, research and departmental responsibilities beyond these examples. The MCQs and flashcards sample all eight domains without claiming official percentages. NBEMS sources establish examination scope and format; IAEA publications support scientific principles, while the cited clinical summaries, pathology guidance and prescribing information support specific clinical teaching.
Guidelines for Competency Based Training Programme in DNB–Radio Therapy · Radiation Oncology Physics: A Handbook for Teachers and Students · Radiation Biology: A Handbook for Teachers and Students
This is independent educational material for India’s postgraduate DNB Radiation Oncology specialty exit examination, awarded by NBEMS. The current curriculum index links Radiation Oncology to the legacy-titled DNB–Radio Therapy curriculum. The original MCQs and flashcards support learning; they do not reproduce NBEMS papers or predict examination results.
Outline used: Reviewed 2026-10-09. NBEMS's current curriculum index lists Radiation Oncology but links to the undated competency-based curriculum titled DNB–Radio Therapy. This legacy specialty title is mapped to current DNB Radiation Oncology using the official index and June 2026 DNB Final bulletin. No curriculum edition or effective date is stated. The June 2026 bulletin, whose filename identifies V1 dated 23.04.2026, verifies the exit examination and current specialty name; it does not establish a new syllabus effective date.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Basic Sciencesnot stated
1.How does lymphatic anatomy guide regional treatment?
Lymphatic drainage connects a primary tumour to anatomically defined nodal basins, making cross-sectional anatomy essential for staging and regional irradiation. In breast cancer, axillary, infraclavicular, supraclavicular and internal mammary nodes represent different regional locations. Their involvement must be interpreted with the primary tumour, surgery and systemic risk. A regional target is selected from disease distribution and recurrence risk; it is not created by expanding every visible node uniformly.
Apply it
A breast planning scan shows a suspicious node medial to the upper ribs rather than within the axilla. Identify its anatomical basin and reconcile imaging with the clinical staging record before deciding regional coverage.
Common pitfall: Calling every ipsilateral thoracic node axillary can misclassify disease and misdirect contours. Anatomical location and the applicable staging definitions must both be checked.
2.What distinguishes tumour grade from anatomical stage?
Grade describes microscopic differentiation and related biological features, whereas anatomical stage describes disease extent through the primary tumour, regional nodes and distant spread. A small tumour can have aggressive histology, and a well-differentiated tumour can still be anatomically extensive. Modern prognostic classifications may additionally incorporate biomarkers, so the staging system must be named. Treatment reasoning should preserve the distinction between what the tumour looks like and where it has spread.
Apply it
A patient has a small breast primary with high histological grade and no identified nodal disease. Explain why the grade raises biological concern without automatically converting the tumour into anatomically advanced disease.
Common pitfall: Using high grade as a synonym for metastatic disease confuses biology with extent. Conversely, a low anatomical stage does not establish indolent behaviour.
3.What does absorbed dose measure?
Absorbed dose measures energy imparted by ionizing radiation per unit mass, expressed in gray, where one gray equals one joule per kilogram. Activity instead measures nuclear transformations per second and is expressed in becquerel. The same source activity can produce different tissue doses because geometry, exposure time, attenuation and radiation energy differ. A clinical dose statement therefore requires a specified location or volume and cannot be replaced by a source activity alone.
Apply it
Two identical radioactive sources remain near tissue for different durations. Their activities are equal, but the longer exposure delivers more energy. Explain why source strength alone cannot document the absorbed treatment dose.
Common pitfall: Treating becquerel and gray as interchangeable ignores source geometry and energy deposition. Equivalent or effective dose quantities also do not replace therapeutic absorbed-dose prescription.
Radiation Oncology Physics: A Handbook for Teachers and Students
4.How does the inverse-square law change dose rate?
For an approximately point-like source in free space, intensity and dose rate vary inversely with the square of distance. Thus the ratio at two positions is the square of the original distance divided by the new distance. Doubling distance reduces the idealized rate to one quarter. Clinical calculations must separately account for attenuation, scatter, source extent and beam geometry; the inverse-square relationship alone describes geometric dilution rather than every influence on patient dose.
Apply it
An idealized source gives 8 units of dose rate at 50 cm. At 100 cm, with attenuation and scatter excluded, calculate 8 × (50/100)² = 2 units and state the assumptions.
Common pitfall: Halving dose rate when distance doubles applies a linear rule incorrectly. Using the ideal relationship near an extended source can also produce substantial error.
Radiation Oncology Physics: A Handbook for Teachers and Students
5.How is radioactive decay incorporated into treatment timing?
Radioactive activity falls exponentially according to A = A₀ × 2^(−t/T½), where T½ is the physical half-life. After each half-life, half the preceding activity remains. If geometry and prescribed dose are unchanged, a lower source dose rate generally requires a longer irradiation time. Physical decay differs from biological clearance; an effective half-life for material within the body combines both processes rather than replacing one with the other.
Apply it
A sealed source has one quarter of its reference activity after two physical half-lives. For an otherwise identical irradiation, estimate a fourfold exposure-time increase, subject to the treatment system’s calibrated source-strength calculation.
Common pitfall: Subtracting the same activity each month assumes linear decay. Biological clearance must not be added to the physical decay of a sealed external source.
Radiation Oncology Physics: A Handbook for Teachers and Students
6.Which photon interactions explain tissue-dependent attenuation?
Photoelectric absorption transfers photon energy to an electron and shows a strong dependence on atomic number and photon energy. Compton scattering transfers part of the energy to an electron while producing a scattered photon; its contribution in tissue is closely related to electron density. These differing dependencies help explain strong bone contrast at diagnostic energies and the importance of Compton interactions for megavoltage treatment photons in soft tissue. Dominance depends on both material and energy.
Apply it
A trainee expects bone-to-soft-tissue contrast on a megavoltage portal image to match a diagnostic radiograph. Use the different interaction contributions to explain why the contrast is reduced despite recognizable skeletal landmarks.
Common pitfall: Declaring one interaction dominant at every energy ignores the material and energy range. Photon attenuation also does not mean all energy is absorbed locally.
Radiation Oncology Physics: A Handbook for Teachers and Students
7.Why do megavoltage photons show skin sparing?
Megavoltage photons generate secondary electrons that deposit energy along their paths. Near the surface, the electron fluence builds with depth before reaching a dose maximum, producing a relatively lower entrance dose than at that maximum. This build-up region explains skin sparing. Surface dose still depends on field size, obliquity, contaminating electrons and materials near the patient, so skin sparing is a physical tendency rather than a guarantee of low skin toxicity.
Apply it
A deep target is adequately covered, but superficial disease receives insufficient dose in the build-up region. Explain why increasing beam energy alone may worsen the superficial coverage problem rather than solve it.
Common pitfall: Assuming the skin receives no dose with megavoltage treatment overlooks electron contamination and beam arrangement. A deeper dose maximum does not assure superficial target coverage.
Radiation Oncology Physics: A Handbook for Teachers and Students
8.When does bolus improve superficial coverage?
Bolus is tissue-equivalent material placed on the patient to alter build-up and the effective treatment surface. For photon treatment, it can raise surface dose by shifting the build-up region into the added material. It can also compensate for missing tissue or modify electron penetration. Thickness, placement and contact must match the planned use. An air gap or inconsistent application can change the intended distribution and compromise reproducibility.
Apply it
A superficial chest-wall target is undercovered without bolus. Select a planned bolus arrangement, document when it is used, and check contact at each fraction rather than adding material informally after treatment planning.
Common pitfall: Bolus is tempting as a universal planning fix, but it deliberately increases superficial dose and can worsen skin reactions when the superficial tissue is not targeted.
Radiation Oncology Physics: A Handbook for Teachers and Students
9.How does electron range influence modality selection?
Clinical electron beams deposit substantial dose near the surface and then fall off over a finite depth range, making them useful for selected superficial targets. Photon beams penetrate more deeply and retain an exit-dose component. Electron selection requires attention to target depth, field size, obliquity, surface contour and tissue heterogeneity. The rapid distal fall-off is useful only when the entire target remains inside the adequately covered depth region.
Apply it
A shallow skin lesion overlies a curved surface near an air cavity. Consider electrons for depth limitation, but evaluate contour and heterogeneity effects before choosing energy or accepting coverage from a flat-water depth-dose curve.
Common pitfall: Choosing electrons solely because a lesion is visible on skin ignores its deep extent. Small fields and irregular surfaces can invalidate simple range expectations.
Radiation Oncology Physics: A Handbook for Teachers and Students
10.Why does proton range require attention to tissue changes?
Protons lose energy as they travel and deposit a pronounced dose near the end of their range, described by the Bragg peak. Combining ranges can cover a target while reducing distal dose compared with many photon arrangements. The endpoint depends on the stopping properties of tissues traversed. Changes in anatomy or density can shift that endpoint, so a sharp distal gradient creates both a dosimetric opportunity and sensitivity to range uncertainty.
Apply it
A proton beam traverses a sinus that changes from fluid-filled to air-filled during treatment. Explain how altered stopping conditions could move the distal dose distribution and prompt review of the original plan’s robustness.
Common pitfall: A sharp Bragg peak does not guarantee a superior clinical plan. Range uncertainty, target motion and normal tissues beyond the target remain central considerations.
Radiation Oncology Physics: A Handbook for Teachers and Students
11.What separates GTV, CTV and PTV?
The gross tumour volume represents demonstrable disease. The clinical target volume contains gross disease and/or subclinical microscopic disease requiring treatment. The planning target volume is a geometrical construct that accounts for uncertainties affecting delivery to the clinical target. These volumes answer different questions: demonstrable extent, biological treatment extent and positional reliability. Their relationship depends on clinical setting, imaging, motion management and verification; margins should follow identified risks rather than an unexplained uniform expansion.
Apply it
A visible primary is contoured on planning CT. Include it with clinically justified microscopic coverage in the CTV, then address setup and motion uncertainty separately when constructing the PTV for the intended verification method.
Common pitfall: Using a larger PTV to compensate for an incorrectly defined CTV confuses uncertainty with microscopic spread. Perfect positioning cannot rescue an omitted biological target.
Radiation Oncology Physics: A Handbook for Teachers and Students
12.Why does oxygen increase low-LET radiation injury?
Low-LET radiation produces direct DNA damage and indirect injury through radicals generated in surrounding material. Oxygen can react with radiation-induced molecular damage and make it less chemically reversible, increasing cell killing. Hypoxic tumour cells are consequently more resistant to low-LET irradiation than comparable oxygenated cells. Reoxygenation between fractions can expose previously resistant cells to a more sensitive state, although tumour oxygenation is heterogeneous and cannot be inferred reliably from tumour size alone.
Apply it
Two otherwise comparable cell populations receive the same low-LET dose under oxygenated and severely hypoxic conditions. Predict greater survival in the hypoxic population and explain why fractionated treatment may partly exploit subsequent reoxygenation.
Common pitfall: Equating oxygen enhancement with increased physical absorbed dose confuses biological effect with energy deposition. Oxygen dependence also differs between low-LET and high-LET radiation.
13.How do the four Rs explain fractionated radiotherapy?
Repair allows cells to resolve some sublethal injury between exposures. Redistribution changes the proportions of cells in differently sensitive cell-cycle phases. Reoxygenation can increase the sensitivity of surviving hypoxic tumour cells. Repopulation increases cell numbers during the treatment course and can offset killing. Fractionation therefore changes more than the total dose delivered: it changes when biological processes occur. The therapeutic effect depends on how these processes differ between tumour and normal tissues.
Apply it
A trainee argues that splitting a dose into fractions only improves patient convenience. Explain how repair may spare normal tissue while redistribution and reoxygenation alter tumour response, with repopulation potentially reducing control during prolonged treatment.
Common pitfall: Assuming all four Rs always improve tumour control overlooks repopulation. The balance also varies by tumour biology, tissue type, fraction interval and overall treatment time.
14.Why are low-alpha/beta tissues sensitive to fraction size?
In the linear-quadratic model, cell effect contains a linear component proportional to dose and a quadratic component proportional to dose squared. The alpha/beta ratio identifies the dose where those components are equal. A lower ratio indicates greater sensitivity to changes in dose per fraction, commonly relevant to late normal-tissue effects. Equal total physical doses can therefore have different biological consequences. Model-based comparisons still require stated tissue assumptions and attention to clinical evidence.
Apply it
Compare two hypothetical courses with equal total dose but different fraction sizes. For a late-effect tissue assigned a low alpha/beta ratio, predict greater modeled injury from larger fractions, assuming complete repair between fractions.
Common pitfall: Assuming every tumour has a high alpha/beta ratio is unjustified. A model parameter is tissue- and endpoint-dependent, and total dose alone cannot establish equivalence.
15.How are BED and EQD2 calculated?
For equal fractions with complete inter-fraction repair, BED = nd[1 + d/(alpha/beta)], where n is fraction number and d is fraction dose. EQD2 divides BED by [1 + 2/(alpha/beta)] to express an equivalent dose in 2-Gy fractions. Both quantities depend on the selected tissue endpoint. These simple equations do not automatically include repopulation, incomplete repair or every uncertainty at very large fraction sizes, so the assumptions must accompany the result.
Apply it
For an educational course of 30 Gy in 10 fractions and alpha/beta = 10 Gy, calculate BED = 39 Gy₁₀ and EQD2 = 32.5 Gy. These values compare modeled effect, not treatment suitability.
Common pitfall: Adding BED values calculated with different alpha/beta ratios is invalid. An apparently precise EQD2 also cannot establish that different irradiated tissue volumes are biologically interchangeable.
Management of Cervical Cancer: Strategies for Limited-resource Centres · Radiation Biology: A Handbook for Teachers and Students
16.How does dose rate affect repair during irradiation?
When radiation is delivered over a longer interval, repair can occur while dose is still accumulating. For many low-LET exposures, this reduces biological effect compared with the same physical dose delivered rapidly. The magnitude depends on tissue repair kinetics, total exposure time and radiation quality. Low-dose-rate, high-dose-rate and pulsed brachytherapy therefore cannot be compared using physical dose alone; their temporal patterns determine how much injury can be repaired during and between exposures.
Apply it
Two brachytherapy schedules deliver equal physical dose over markedly different durations. Explain why the prolonged exposure may permit more repair, and identify repair assumptions needed before using a biological equivalence calculation to compare them.
Common pitfall: Applying the simple complete-repair fractionation equation to continuous irradiation ignores repair during delivery. Equal source activity also does not establish equal dose rate at tissue.
17.How do absolute and relative treatment benefits differ?
Absolute risk reduction subtracts the treated event risk from the control risk over a specified follow-up period. Relative risk reduction divides that difference by the control risk. Number needed to treat is the reciprocal of absolute risk reduction when risks are expressed as proportions and the comparison is appropriate. Relative benefit can look substantial when baseline risk is small. Interpretation therefore requires the endpoint, follow-up period, uncertainty and treatment harms alongside the effect measure.
Apply it
In a fictional trial, five-year recurrence falls from 20% to 15%. Calculate a five-percentage-point absolute reduction, a 25% relative reduction and an NNT of 20 over five years, then consider the uncertainty around those estimates.
Common pitfall: Calling a five-percentage-point decrease a 5% relative reduction mixes scales. NNT without its outcome and time horizon can also mislead clinical comparisons.
Guidelines for Competency Based Training Programme in DNB–Radio Therapy · Chapter 15: Interpreting results and drawing conclusions | Cochrane
18.What does censoring mean in survival analysis?
Censoring records that an individual’s event time is known only beyond the last observed event-free time. In Kaplan–Meier analysis, that person contributes information while observed and then leaves the risk set without being counted as an event. This differs from assuming permanent survival or immediate failure. Valid interpretation depends on whether censoring is sufficiently independent of prognosis; substantial informative loss to follow-up can bias an apparently favourable survival curve.
Apply it
A participant remains alive at the final documented review and then cannot be contacted. Censor follow-up at that review for overall-survival analysis; do not assign death at disappearance or survival to the study’s final date.
Common pitfall: A flat tail with very few participants at risk is not strong evidence of durable survival. Always inspect follow-up maturity and the numbers at risk.
Guidelines for Competency Based Training Programme in DNB–Radio Therapy · download
Clinical Radiotherapynot stated
19.Why must simulation reproduce the treatment position?
Planning images describe anatomy in a particular position and configuration. Immobilization, arm placement, support devices and relevant organ preparation should therefore be reproducible during delivery. A technically accurate dose calculation cannot compensate for a systematic mismatch between simulation and treatment. The chosen position must also be tolerable for the patient throughout the course. Reproducibility is established through practical setup assessment and verification rather than assumed from a well-fitting device alone.
Apply it
A patient can maintain an elevated-arm position during a brief scan but develops severe pain before a treatment fraction ends. Reassess the position and immobilization before accepting a plan that depends on unsustainable daily positioning.
Common pitfall: Selecting the position with the best initial image while ignoring daily tolerability creates systematic delivery risk. Immobilization reduces uncertainty but does not eliminate verification needs.
Clinical Training of Medical Physicists Specializing in Radiation Oncology
20.What can a dose-volume histogram reveal?
A cumulative dose-volume histogram shows the volume receiving at least each stated dose. It summarizes target coverage and organ exposure but discards the spatial location of those doses. D95 describes a dose received by 95% of the specified volume, while V20 describes the volume receiving at least 20 Gy when that convention is used. A plan should be judged with both histogram metrics and spatial dose distributions, using correctly defined structures.
Apply it
Two plans have nearly identical target histograms, but one places its hotspot beside a critical structure. Inspect the axial dose distribution and relevant organ metrics before considering the plans equivalent on their target summaries alone.
Common pitfall: A favourable DVH can conceal a geographically important cold spot or hotspot. Confusing a dose metric with a volume metric further distorts plan interpretation.
Clinical Training of Medical Physicists Specializing in Radiation Oncology · Radiation Oncology Physics: A Handbook for Teachers and Students
21.How should respiratory motion influence target planning?
Respiration can move a tumour and nearby organs during irradiation, so a single free-breathing image may not represent their full positional range. Motion assessment can inform an internal target approach or a strategy such as gating, breath hold or tracking. The selected method must be consistent across simulation, planning, verification and delivery. A smaller motion-related margin is justified only when the chosen strategy reliably controls or accounts for the measured uncertainty.
Apply it
A lower-lobe lung lesion moves substantially between respiratory phases. Review motion-resolved imaging and select a reproducible management strategy before reducing margins simply because daily image guidance is available at the treatment unit.
Common pitfall: Pretreatment alignment checks one time point and does not automatically control motion during beam delivery. Irregular breathing can also undermine assumptions from a single simulation.
Clinical Training of Medical Physicists Specializing in Radiation Oncology
22.How does image guidance distinguish systematic from random error?
A systematic setup error tends to persist across fractions, shifting the delivered distribution repeatedly in the same direction. Random errors vary between fractions and tend to broaden the accumulated distribution. Repeated image-guidance records can distinguish these patterns and guide correction. Alignment should use anatomy relevant to the target; matching bone alone may not represent a mobile soft-tissue target. Correction protocols must also consider residual rotational error and anatomical change.
Apply it
Daily images show a similar displacement over several fractions despite apparently reproducible skin marks. Investigate and correct the persistent setup discrepancy instead of assuming it will average away as treatment proceeds over subsequent fractions.
Common pitfall: Averaging is an attractive explanation for repeated errors, but a consistent displacement remains systematic. Image guidance also cannot correct an incorrect target contour.
Clinical Training of Medical Physicists Specializing in Radiation Oncology
23.Why is brachytherapy central to definitive cervical irradiation?
Brachytherapy places a radiation source close to the cervical tumour, allowing a high local dose with rapid dose fall-off away from the source. This geometry supports tumour dose escalation while limiting exposure of adjacent pelvic organs. In definitive radiation treatment for appropriate cervical cancer presentations, brachytherapy is an integral component rather than an optional convenience. External-beam conformality does not automatically reproduce its distribution, particularly around a central pelvic target.
Apply it
A patient undergoing definitive cervical chemoradiation is offered an external-beam boost solely because applicator scheduling is inconvenient. Explain the geometric value of brachytherapy and arrange appropriate specialist assessment rather than assuming the techniques are interchangeable.
Common pitfall: Equating a conformal external-beam boost with brachytherapy on prescription dose alone ignores dose distribution. Applicator feasibility and disease extent require assessment, not casual substitution.
Cervical Cancer Treatment (PDQ), Health Professional Version · Management of Cervical Cancer: Strategies for Limited-resource Centres
24.How are cervical brachytherapy organ doses interpreted?
The bladder, rectum and sigmoid are important organs at risk near cervical brachytherapy applicators. D2cc is the minimum dose to the most irradiated 2 cm³ of the specified organ. A rectal D2cc of 5 Gy means that the hottest 2 cm³ receives at least 5 Gy; it does not specify that volume's mean dose or maximum dose. Organ position and applicator geometry strongly affect this quantity. External-beam and brachytherapy contributions require appropriate EQD2 conversion when combining different fraction sizes.
Apply it
Interpret a bladder D2cc of 6 Gy: the most irradiated 2 cm³ receives at least 6 Gy, but some tissue may receive more. If rectal D2cc rises between insertions despite similar target coverage, inspect organ contours, applicator position and the spatial dose distribution before adjusting dwell positions or times.
Common pitfall: D2cc is neither the whole-organ mean nor a point maximum. Adding physical doses ignores fraction-size effects. Summing per-fraction D2cc values after biological conversion also does not prove that the same tissue occupied the hottest volume each time; organ movement and deformation limit exact spatial interpretation.
Management of Cervical Cancer: Strategies for Limited-resource Centres · Source
25.Why is irradiation commonly used after breast-conserving surgery?
Breast-conserving surgery removes the identified tumour, while postoperative irradiation reduces recurrence from residual microscopic disease within the breast. PRIME II studied omission in patients aged at least 65 years with hormone-receptor-positive, node-negative tumours no larger than 3 cm, clear margins and endocrine therapy. Omission increased local recurrence despite similar overall survival. These eligibility features define an evidence-based discussion, not a universal omission rule. Target selection and omission decisions also require consideration of pathology, endocrine treatment adherence, life expectancy and the patient’s priorities.
Apply it
A 68-year-old with a 2-cm hormone-receptor-positive, node-negative tumour, clear margins and planned endocrine therapy asks about omission. Explain the higher local recurrence risk without irradiation and the similar overall survival observed in PRIME II, then discuss how those outcomes fit the patient’s circumstances.
Common pitfall: Age at least 65 years alone does not establish suitability for omission. Similar overall survival does not mean equal local control, and trial eligibility is not an automatic treatment recommendation.
26.How can deep inspiration reduce cardiac exposure?
During deep inspiration, thoracic geometry changes and the heart may move farther from portions of the left breast or chest-wall treatment region. A reproducible breath-hold technique can therefore reduce cardiac exposure in suitable patients. Benefit must be demonstrated on the individual plan while preserving target coverage. The intervention depends on coaching, monitoring and repeatability; the ability to take one deep breath during consultation does not establish reliable treatment delivery.
Apply it
A left-sided breast plan exposes more heart than desired. Compare a coached breath-hold planning dataset with the original geometry and confirm both cardiac improvement and reproducibility before choosing the technique for the treatment course.
Common pitfall: Assuming breath hold always improves every organ metric overlooks individual geometry. Apparent dosimetric benefit is insufficient if the position cannot be reproduced during irradiation.
Breast Cancer Treatment (PDQ), Health Professional Version · Clinical Training of Medical Physicists Specializing in Radiation Oncology
27.When is SBRT appropriate for early NSCLC?
Stereotactic body radiotherapy delivers highly conformal treatment in a small number of fractions with rigorous localization and motion management. It is an established option for appropriately staged, medically inoperable stage I non-small-cell lung cancer. Suitability depends on tumour size, location, adjacent organs and the reliability of staging and diagnosis. A central or otherwise high-risk location changes planning considerations; the label SBRT does not make one fractionation approach suitable for every lung lesion.
Apply it
A patient has a peripheral, node-negative stage I NSCLC and prohibitive operative risk. Discuss SBRT after appropriate staging and motion assessment rather than treating surgical inoperability as evidence that only symptom-directed care is possible.
Common pitfall: Extending an early-stage SBRT approach to bulky nodal disease ignores treatment volume and disease biology. Central lesions also require distinct attention to adjacent critical structures.
Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
28.Why does concurrent treatment require careful selection in stage III NSCLC?
For suitable patients with unresectable stage III NSCLC, concurrent chemoradiation combines thoracic local treatment with systemic therapy during the same interval. Concurrent treatment can improve outcomes compared with sequential approaches in selected populations, while increasing important toxicities, including oesophageal injury. Performance status, organ function, disease volume and treatment feasibility influence selection. The decision also requires multidisciplinary assessment of resectability and subsequent systemic options rather than using stage III as a single uniform treatment category.
Apply it
Two patients have unresectable stage III NSCLC, but one has substantially poorer functional reserve and a large thoracic treatment volume. Explain why the same concurrent approach cannot be selected solely from their shared stage designation.
Common pitfall: Treating concurrent therapy as mandatory for every stage III patient ignores fitness and toxicity. Conversely, chronological age alone does not establish inability to tolerate combined treatment.
Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
29.Why does glioblastoma require combined local and systemic treatment?
Glioblastoma infiltrates beyond the visibly enhancing mass, so removing the apparent lesion does not usually remove all disease. For suitable patients, maximal safe surgery followed by radiotherapy with temozolomide and subsequent temozolomide is an established combined approach. Treatment selection considers age, functional status and molecular findings. The word safe matters because neurological preservation affects both quality of life and treatment tolerance; complete removal on imaging is not equivalent to biological eradication.
Apply it
Postoperative MRI shows no residual enhancing tumour in a fit adult with glioblastoma. Explain why this finding supports assessment of surgical extent but does not remove the rationale for subsequent chemoradiation against infiltrative disease.
Common pitfall: Equating absence of enhancement with absence of tumour overlooks microscopic infiltration. More extensive surgery is also not automatically beneficial when it causes major neurological disability.
Central Nervous System Tumors Treatment (PDQ), Health Professional Version
30.When does p16 require HPV-specific interpretation?
For oropharyngeal tissue specimens, CAP defines positive p16 immunohistochemistry as nuclear and cytoplasmic staining of moderate-to-strong intensity in at least 70% of tumour cells. Equivocal patterns include moderate-to-strong nuclear and cytoplasmic staining in at least 50% but less than 70% of tumour cells, and extensive but weak staining. HPV-specific testing is indicated for these patterns, morphological discordance, low-prevalence geographical settings, large multisite tumours overlapping the oropharynx, non-tonsillar and non-base-of-tongue oropharyngeal sites, and relevant clinical-trial requirements. For FNA specimens, HPV-specific testing is recommended; p16 may be used in selected circumstances. Negative FNA HPV testing should be repeated on tissue if it becomes available.
Apply it
An oropharyngeal tissue sample with moderate-to-strong nuclear and cytoplasmic staining in 60% of tumour cells is equivocal and requires HPV-specific testing. Exactly 70% with the required intensity meets the positivity threshold. Extensive weak staining remains equivocal even when more than 70% of cells stain. Apply the separate FNA recommendation to a nodal aspirate.
Common pitfall: Percentage, intensity and nuclear plus cytoplasmic distribution must be assessed together. Strong staining in a small proportion of cells does not satisfy the tissue positivity criterion. Positive p16 is a surrogate result and does not remove additional-testing indications arising from morphology, geographical prevalence, anatomical site or clinical-trial requirements.
Human Papillomavirus Testing in Head and Neck Carcinomas · hpv-head-neck-update-summary-recommendations.pdf · CAP Protocol for HPV-Associated Oropharyngeal Carcinoma Resection, Version 1.1.0.0
31.How are pathological nodes classified in Version 9 HPV-associated oropharyngeal carcinoma?
AJCC Version 9 for HPV-associated oropharyngeal carcinoma became effective on 1 January 2026. Pathological nodal classification incorporates positive-node count and pathological extranodal extension. For example, two positive nodes with pathological extranodal extension meet pN2 criteria; more than four positive nodes with extranodal extension meet pN3 criteria. Clinical TNM uses clinical assessment, whereas pathological TNM uses the applicable resection findings. The clinical and pathological nodal systems are distinct and cannot be interchanged by merely changing the prefix.
Apply it
After primary resection and neck dissection for confirmed HPV-associated oropharyngeal carcinoma, two nodes contain metastases with pathological extranodal extension. Assign pN2. In a separate resection with five positive nodes and extranodal extension, assign pN3. These are nodal categories, not complete stage groups.
Common pitfall: Using node count alone omits a treatment-relevant pathological feature. Applying clinical nodal categories to a neck-dissection result or carrying forward older pathological criteria can misclassify disease; a staging update alone does not authorize treatment de-escalation.
New AJCC Staging System Protocols for Salivary Glands and Oropharynx Are Live · CAP Protocol for HPV-Associated Oropharyngeal Carcinoma Resection, Version 1.1.0.0
32.How does IMRT reduce salivary toxicity?
Intensity-modulated radiotherapy varies beam fluence to shape dose around targets and organs at risk. In head-and-neck treatment, this can lower dose to salivary glands and reduce xerostomia compared with less conformal approaches. The benefit depends on actual gland exposure and adequate target delineation, not the technique name alone. Parotid sparing must be balanced with disease coverage, and oral dryness can also reflect dose to other salivary tissues and non-radiation factors.
Apply it
A patient with oropharyngeal cancer has disease near one parotid gland. Optimize feasible salivary sparing while preserving clinically justified target coverage, and explain why both glands may not be equally spareable in this anatomy.
Common pitfall: Prioritizing a low parotid mean dose over coverage of established disease sacrifices the treatment objective. IMRT reduces xerostomia risk but does not guarantee normal salivation.
Oropharyngeal Cancer Treatment (PDQ), Health Professional Version
33.How should treatment be sequenced for locally advanced rectal cancer compared with favourable early-stage disease?
Consider a fit patient with mismatch-repair-proficient, low rectal adenocarcinoma staged cT3N2M0, with a threatened circumferential resection margin. Total neoadjuvant therapy delivers both systemic chemotherapy and pelvic radiation or chemoradiation before planned surgery. One defined sequence is long-course pelvic chemoradiation with concurrent capecitabine, followed by consolidation FOLFOX chemotherapy, then restaging and planned total mesorectal excision. Chemoradiation addresses pelvic disease and promotes tumour regression; systemic chemotherapy treats potential micrometastatic disease. A threatened margin makes achieving a microscopically clear, R0 resection a central preoperative objective.
Apply it
For this nonmetastatic, node-positive case, explain the sequence as chemoradiation, systemic chemotherapy, reassessment and surgery. By comparison, a favourable cT2N0M0 mid-rectal tumour with clear anticipated margins can undergo upfront oncological resection with total mesorectal excision, without routine neoadjuvant pelvic irradiation. Surgical pathology then determines whether additional treatment is indicated.
Common pitfall: Total neoadjuvant therapy does not mean chemotherapy alone before surgery: both systemic chemotherapy and radiation-based treatment occur preoperatively. Induction chemotherapy followed by chemoradiation is another possible sequence. Do not apply radiation-omission strategies intended for selected lower-risk presentations to a threatened-margin tumour. Preoperative regression aims to improve the prospect of clear margins; it does not guarantee an R0 resection or automatically eliminate the planned operation.
34.How do acute and late radiation effects differ?
Acute effects commonly involve rapidly renewing tissues and can appear during treatment or soon afterward as normal-cell depletion becomes clinically apparent. Late effects may develop after a longer interval and involve vascular, stromal and organ-specific injury. Their dose-volume and fractionation sensitivities can differ. Severity should be described with a specified grading system and clinical context. A mild acute reaction does not prove that late toxicity risk is low, and severe symptoms require assessment for alternative causes.
Apply it
A patient develops mucositis during head-and-neck treatment and asks whether its eventual resolution guarantees freedom from later fibrosis. Explain the different tissue processes and why supportive care and long-term dose-volume assessment answer different questions.
Common pitfall: Using acute skin reaction as a complete measure of organ tolerance ignores late endpoints. Symptoms during radiotherapy should not automatically be attributed to radiation alone.
35.Why can unplanned treatment prolongation reduce tumour control?
Surviving tumour clonogens can proliferate during a radiotherapy course, and repopulation may accelerate in some tumours after treatment begins. Prolonging overall treatment time can therefore reduce tumour effect even when the original physical dose is eventually delivered. The importance varies by tumour type, interruption timing and schedule. Compensation requires a supervised biological and clinical assessment because additional dose or altered timing may also increase normal-tissue injury; an arithmetic replacement of missed fractions is insufficient.
Apply it
A patient receiving curative head-and-neck irradiation misses several fractions because of manageable treatment toxicity. Address the cause promptly and review overall treatment time and any compensation strategy with the treating team rather than merely appending dates.
Common pitfall: Delivering the original fraction count eventually does not guarantee the original tumour effect. Adding extra fractions without considering normal-tissue risk can create a second problem.
36.When does back pain suggest metastatic cord compression, and what immediate actions are required?
In a patient with cancer, progressive spinal pain accompanied by weakness, sensory change, gait disturbance or bladder or bowel dysfunction suggests metastatic spinal cord or cauda equina compression. Immediately contact the specialist MSCC or acute oncology service. NICE NG234 recommends whole-spine MRI as soon as possible and always within 24 hours. For neurological symptoms or signs, give 16 mg oral dexamethasone or an equivalent parenteral dose promptly, then continue 16 mg daily while awaiting surgery or radiotherapy. Start immobilisation without delay when instability is suspected. These are clinical guidance recommendations.
Apply it
A patient with metastatic cancer develops thoracic pain, new leg weakness and severe pain on movement. Escalate immediately, give dexamethasone promptly and arrange urgent whole-spine MRI. Protect the spine during nursing and transfers while stability is assessed. Imaging and multidisciplinary review determine the roles of decompression, stabilisation and radiotherapy.
Common pitfall: Do not wait for paralysis, sphincter dysfunction or MRI confirmation before starting dexamethasone when neurological symptoms or signs suggest MSCC. Imaging only the painful segment can miss disease elsewhere. Analgesic relief does not establish spinal stability, and mobilisation before assessment can be hazardous when instability is suspected.
Cancer Pain (PDQ), Health Professional Version · Recommendations | Spinal metastases and metastatic spinal cord compression | Guidance | NICE
Clinical Cancer Chemotherapynot stated
37.Why are anticancer drugs combined?
A rational drug combination seeks complementary activity against cancer cells while limiting overlapping dose-limiting toxicities and resistance mechanisms. Drugs may act at different cellular targets or cell-cycle stages, but mechanistic diversity alone does not prove clinical benefit. A combination must also be deliverable at effective exposures with acceptable organ toxicity. Evidence from the relevant disease setting is essential because adding an active agent can increase harm without improving the outcome that matters.
Apply it
Two proposed agents have different molecular targets but both cause substantial marrow suppression. Explain why different mechanisms do not automatically make the combination suitable, and examine clinical evidence, overlapping toxicity and feasible treatment intensity before selection.
Common pitfall: Assuming that more active drugs always produce better treatment ignores tolerability and demonstrated benefit. Non-overlapping mechanisms do not guarantee non-overlapping toxicity or absence of resistance.
Guidelines for Competency Based Training Programme in DNB–Radio Therapy · Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
38.How does concurrent chemotherapy alter radiotherapy effects?
Concurrent chemotherapy can increase tumour response through radiosensitization while also treating disease outside the radiation field, depending on the agent and regimen. The same interaction may increase normal-tissue toxicity, particularly within irradiated tissues. Concurrent and sequential schedules therefore represent different biological and tolerability choices rather than interchangeable calendars. Selection depends on disease-specific evidence, patient fitness, organ function and the feasibility of completing the intended radiotherapy course without harmful interruption.
Apply it
A patient asks why chemotherapy during thoracic irradiation is associated with more swallowing difficulty than a sequential schedule. Explain the interaction in irradiated normal tissue while discussing why concurrent treatment may still offer benefit in suitable patients.
Common pitfall: Calling chemotherapy a radiosensitizer does not mean it sensitizes only tumour cells. A beneficial concurrent regimen in one cancer cannot automatically be transferred to another.
Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version · Guidelines for Competency Based Training Programme in DNB–Radio Therapy
39.Why does prior anthracycline exposure matter before doxorubicin?
Doxorubicin can cause cardiomyopathy, with risk related to cumulative exposure and influenced by other cardiac risk factors and cardiotoxic treatments. Injury may appear during therapy or after treatment has ended. Assessment therefore includes prior anthracycline history and cardiac function rather than only the current cycle’s planned dose. A normal baseline measurement does not remove cumulative risk. Decisions should use the prescribing information and the patient’s complete treatment and cardiovascular history.
Apply it
A patient scheduled for doxorubicin previously received an anthracycline elsewhere. Obtain the prior treatment record and review cumulative exposure and cardiac assessment before treating the proposed course as a first exposure to the drug class.
Common pitfall: Counting only the present regimen overlooks earlier anthracyclines. Absence of cardiac symptoms or a normal initial ejection fraction does not eliminate the possibility of treatment-related cardiomyopathy.
Doxorubicin Hydrochloride Injection: Prescribing Information
40.How should suspected doxorubicin extravasation be recognized?
Doxorubicin is a vesicant, and leakage outside the vein can cause severe local tissue injury and necrosis. Burning, pain, swelling or altered infusion-site appearance during administration should trigger immediate concern. The infusion must be stopped and the site managed promptly under the extravasation procedure, preserving access for appropriate aspiration when indicated. Continuing because blood return was present earlier is unsafe: a previously satisfactory line does not establish that its current position remains secure.
Apply it
During peripheral doxorubicin infusion, a patient reports new burning and swelling around the cannula. Stop administration immediately, activate the extravasation response and avoid flushing the suspected infiltrated drug further into surrounding tissue at the site.
Common pitfall: Restarting the infusion after briefly slowing it can worsen injury. Minimal early skin change does not exclude significant vesicant exposure or delayed tissue damage.
Doxorubicin Hydrochloride Injection: Prescribing Information
41.How do breast biomarkers guide systemic treatment?
Oestrogen and progesterone receptor findings help identify cancers potentially responsive to endocrine treatment, while HER2 status identifies a different targetable pathway. These biomarkers describe treatment-relevant biology and must be interpreted with stage, pathology and patient factors. Tumours of similar size can consequently require different systemic strategies. Biomarker positivity does not establish that one treatment replaces every other indicated modality, and an incomplete or equivocal result may require appropriate pathological clarification.
Apply it
Two patients have similarly sized breast tumours, but one is hormone-receptor positive and the other has HER2-positive disease. Explain why systemic treatment discussions diverge even though their anatomical tumour measurements appear closely comparable at presentation.
Common pitfall: Using tumour size alone to select systemic therapy ignores predictive biology. A positive receptor also does not automatically justify omitting surgery, radiotherapy or other indicated systemic treatment.
42.Why does MGMT methylation influence temozolomide interpretation?
MGMT repairs certain alkylating DNA lesions, including O6-methylguanine damage relevant to temozolomide. Promoter methylation can reduce MGMT expression, making tumour cells less able to repair this damage and associating with greater temozolomide benefit in relevant glioblastoma settings. The marker informs prognosis and treatment interpretation but is not a measure of visible tumour burden. Its influence is particularly important when weighing treatment approaches in patients whose age or functional status limits combined therapy.
Apply it
An older patient with glioblastoma has limited functional reserve and an available MGMT result. Incorporate that molecular information into the treatment discussion rather than selecting temozolomide solely from the postoperative MRI appearance or the tumour’s measured diameter.
Common pitfall: MGMT methylation does not guarantee response, and unmethylated status does not prove universal absence of benefit. Molecular findings must be interpreted within the clinical treatment setting.
Central Nervous System Tumors Treatment (PDQ), Health Professional Version
43.Which findings distinguish pneumonitis grades and determine pembrolizumab withholding or discontinuation?
The pembrolizumab label uses NCI CTCAE v4.0; CTCAE v4.03 provides the grading criteria described here. Grade 1 pneumonitis is asymptomatic, with diagnostic observations only and no intervention indicated. Grade 2 is symptomatic, with medical intervention indicated or limitation of instrumental activities such as shopping or preparing meals. Grade 3 includes severe symptoms, limitation of self-care activities such as bathing or dressing, or an oxygen requirement attributable to pneumonitis. Grade 4 involves life-threatening respiratory compromise requiring urgent intervention. The label specifies withholding pembrolizumab for grade 2 pneumonitis and permanently discontinuing it for grade 3–4 pneumonitis.
Apply it
A patient develops cough and exertional breathlessness with new pulmonary opacities. Symptoms prevent grocery shopping, but the patient can bathe and dress independently and needs no oxygen. After assessment supports immune-mediated pneumonitis and investigates competing causes, these findings support grade 2: withhold pembrolizumab and initiate corticosteroid treatment. If respiratory deterioration creates a new oxygen requirement, this supports grade 3 and permanent discontinuation, even if corticosteroids subsequently improve the symptoms.
Common pitfall: Imaging extent alone does not determine the grade or establish immune causation; evaluate infection, tumour progression and other pulmonary diagnoses. When systemic corticosteroids are required, treat until improvement to grade 1 or less, then taper over at least one month. Resumption after withholding requires recovery to grade 0–1 following corticosteroid taper and satisfaction of the label's criteria. Permanently discontinue if recovery to grade 0–1 does not occur within 12 weeks of starting corticosteroids or prednisone-equivalent treatment cannot be reduced to 10 mg/day or less within that interval. Recurrent grade 2 pneumonitis is not separately listed as an automatic permanent-discontinuation criterion.
KEYTRUDA (Pembrolizumab): Prescribing Information · Organ-Related Inflammation and Immunotherapy · ctcae-v403.pdf
44.How do CTCAE colitis and diarrhea criteria differ when modifying pembrolizumab treatment?
Colitis and diarrhea are separate CTCAE adverse-event terms. Under CTCAE v4.03, colitis grade 1 consists of asymptomatic diagnostic observations without indicated intervention. Abdominal pain, mucus or blood in stool supports grade 2 colitis. Grade 3 descriptors include severe abdominal pain, change in bowel habits, medical intervention indicated or peritoneal signs; semicolons in CTCAE mean 'or', rather than requiring every descriptor. Life-threatening consequences requiring urgent intervention define grade 4. Separately, diarrhea stool-count criteria include fewer than four additional stools daily over baseline for grade 1, four to six for grade 2 and seven or more for grade 3; functional consequences and other listed criteria also affect grading.
Apply it
A patient receiving pembrolizumab reports two additional loose stools daily, moderate abdominal cramps and mucus with blood. There is no severe pain, peritoneal irritation or life-threatening complication. The stool-frequency component fits grade 1 diarrhea, but the inflammatory symptoms support grade 2 colitis. Investigate infectious causes and withhold pembrolizumab for immune-mediated grade 2 colitis. Severe abdominal pain would support grade 3 colitis, whereas life-threatening consequences requiring urgent intervention would establish grade 4.
Common pitfall: A low stool count cannot exclude clinically significant colitis. The pembrolizumab label, using CTCAE v4.0, specifies withholding for grade 2–3 colitis and permanent discontinuation for grade 4. A first grade 3 episode can follow the withholding pathway, but recurrent grade 3 immune-mediated toxicity requiring systemic immunosuppression requires permanent discontinuation. Treat with corticosteroids until improvement to grade 1 or less, then taper over at least one month. Resumption requires recovery to grade 0–1 following taper. Permanently discontinue if recovery does not occur within 12 weeks of starting corticosteroids or prednisone-equivalent treatment cannot be reduced to 10 mg/day or less within that interval. Steroid-refractory disease warrants reassessment for infection and additional immunosuppression.
Organ-Related Inflammation and Immunotherapy · KEYTRUDA (Pembrolizumab): Prescribing Information · ctcae-v403.pdf
Other disciplines allied to Radiotherapy and Oncologynot stated
45.Why is pelvic MRI important in rectal cancer?
Pelvic MRI characterizes rectal tumour extent and its relationship to the mesorectal fascia and surrounding structures. This anatomical information helps estimate the risk of an involved circumferential resection margin and supports multidisciplinary treatment planning. It answers a different question from endoscopic visualization of the luminal lesion or systemic imaging for distant spread. Interpretation requires an appropriate rectal protocol and clinical correlation; a staging label without the relevant anatomical relationships can conceal important surgical risk.
Apply it
A rectal lesion appears modest on endoscopy, but MRI shows extension close to the mesorectal fascia. Use the extramural anatomy in multidisciplinary planning rather than allowing the intraluminal appearance alone to determine the treatment sequence.
Common pitfall: A good endoscopic view does not establish a safe circumferential margin. PET uptake and distant-staging CT also do not replace detailed local pelvic anatomical assessment.
46.Why is FDG uptake not specific for malignancy?
FDG reflects glucose-related metabolic activity and can accumulate in malignant cells, inflammatory cells and normally active tissues. Infection, healing and treatment-related inflammation can therefore produce findings that resemble cancer. Conversely, some malignancies or small lesions may show limited detectable uptake. Interpretation combines uptake pattern with anatomical imaging, timing and clinical context. A PET-positive focus is evidence requiring explanation, not a histological diagnosis, especially when accepting it would substantially change the intent of treatment.
Apply it
A new FDG-avid focus appears near a recently treated inflammatory site and would convert a curative plan to metastatic management. Correlate with anatomy, timing and clinical findings, and seek confirmation when the unresolved finding changes treatment intent.
Common pitfall: An intense focus is not automatically cancer, and a negative scan does not exclude every malignancy. Both false-positive and false-negative mechanisms matter in staging.
47.How should registered imaging be checked before contouring?
Image registration aligns information from different datasets, such as the anatomical detail of MRI with the geometry of planning CT. Accuracy depends on acquisition position, anatomy, distortion and the registration method. A visually plausible match in one region can still be inaccurate near the target. The clinician should inspect relevant landmarks and soft tissues across the region used for decisions, because transferred contours and apparent disease boundaries inherit any registration error.
Apply it
Brain MRI is fused to planning CT, but the target appears displaced relative to nearby anatomy on several slices. Review the registration locally before transferring contours or treating the discrepancy as a true change in tumour location.
Common pitfall: Trusting an automated registration score without anatomical inspection can propagate error. Alignment of distant bones does not prove accurate alignment of the target-bearing soft tissues.
Clinical Training of Medical Physicists Specializing in Radiation Oncology
48.What does a negative surgical margin establish?
A negative margin means tumour is not identified at the assessed specimen boundary under the applicable pathological definition. It describes the resection specimen rather than proving that no malignant cells remain anywhere in the patient. Margin interpretation depends on site, specimen orientation and the disease setting. Adjuvant decisions also consider nodal status, tumour biology and recurrence risk. Surgery, pathology and radiation planning therefore need a shared understanding of where the specimen boundaries correspond to the operative bed.
Apply it
A postoperative breast report records a negative margin, and the patient asks whether all further treatment is unnecessary. Explain what the margin demonstrates and review the independent reasons for local irradiation or systemic treatment in that setting.
Common pitfall: A negative margin is not equivalent to absence of regional or distant risk. An unoriented specimen can also limit how precisely a concerning boundary is localized.
Breast Cancer Treatment (PDQ), Health Professional Version · Guidelines for Competency Based Training Programme in DNB–Radio Therapy
Preventive and community oncologynot stated
49.How does HPV vaccination prevent cancer?
Prophylactic HPV vaccines induce immune protection against infection by covered HPV types, reducing the risk of subsequent HPV-related precancer and cancer. They act before infection establishes disease and do not eradicate an existing HPV infection or treat an established tumour. Protection is strongest when vaccination precedes exposure. Vaccinated individuals may still need cervical screening according to the applicable programme because vaccination does not cover every carcinogenic type or every prior exposure.
Apply it
A person already treated for an HPV-related lesion expects vaccination to remove remaining abnormal cells. Explain its preventive role and distinguish vaccination from the follow-up and treatment needed for established infection or disease in that person.
Common pitfall: Describing vaccination as treatment for existing cancer misstates its mechanism. Vaccination status also does not automatically remove the need for appropriate cervical screening.
50.How does screening differ from diagnostic evaluation?
Screening tests apparently well people to identify those needing further assessment, whereas diagnostic evaluation investigates symptoms, signs or an abnormal screening result. A positive screen does not by itself establish cancer. A negative screen also does not explain away a new concerning symptom, because test sensitivity is imperfect and disease can develop between screening rounds. Prevention programmes require a pathway from testing to confirmation and treatment, not simply a high number of completed tests.
Apply it
A person with new persistent abnormal bleeding reports a recent negative cervical screening result. Arrange diagnostic assessment of the symptom rather than advising that the negative screening result excludes a current clinically important cause.
Common pitfall: Applying an asymptomatic screening interval to a symptomatic patient delays diagnosis. Treating a positive screen as confirmed cancer can instead lead to unnecessary intervention.
Cervical Cancer Treatment (PDQ), Health Professional Version · Guidelines for Competency Based Training Programme in DNB–Radio Therapy
51.What separates cancer incidence from prevalence?
Incidence describes new cancer cases arising in a defined population over a specified period. Prevalence describes people living with the condition at a stated time or during a stated interval. Prevalence is influenced by both new-case occurrence and survival, so it can rise when treatment improves even without an increase in incidence. Comparisons require compatible case definitions, populations and timeframes; raw counts alone cannot establish that one population has a higher individual cancer risk.
Apply it
A district reports more people living after cancer treatment but stable new-case rates. Explain how improved survival can increase prevalence and service demand without demonstrating that the incidence of newly diagnosed cancer has risen in that district.
Common pitfall: Using prevalent survivors as the numerator for an incidence rate mixes measures. Comparing crude counts between populations of different sizes or ages can also mislead.
Guidelines for Competency Based Training Programme in DNB–Radio Therapy · The value of cancer data
52.Why distinguish population-based from hospital-based registries?
A population-based registry seeks cancer cases arising among residents of a defined population, enabling incidence estimates when ascertainment and denominators are appropriate. A hospital-based registry records patients managed at participating institutions and is valuable for service evaluation and clinical patterns. Referral practices influence hospital case mix, so it cannot automatically represent population risk. Data quality requires consistent coding, avoidance of duplicate records and clear definitions of residence, diagnosis and follow-up.
Apply it
A tertiary centre sees a surge in rare tumours after expanding its referral network. Use its hospital registry to assess workload, but avoid claiming a population incidence increase without defined catchment data and appropriate case ascertainment.
Common pitfall: Hospital referral counts are not population incidence rates. Duplicate registrations and inconsistent residence rules can further distort trends even when the underlying diagnoses are correct.
Guidelines for Competency Based Training Programme in DNB–Radio Therapy · The value of cancer data
Palliative carenot stated
53.When should palliative care join cancer treatment?
Palliative care addresses physical symptoms and psychological, social and spiritual concerns associated with serious illness. It can be integrated alongside anticancer treatment from diagnosis onward according to need. Its purpose is to improve quality of life and support patients and families through decisions, rather than waiting until all tumour-directed options are exhausted. Hospice and end-of-life care overlap with palliation but represent more specific care contexts; referral does not itself mean treatment abandonment.
Apply it
A patient starting disease-directed therapy has uncontrolled pain, caregiver distress and uncertainty about treatment goals. Add palliative care now while oncology treatment continues, using the team to address symptoms and support informed, patient-centred decisions.
Common pitfall: Delaying referral until the final days forfeits symptom and communication support. Palliative involvement does not automatically require stopping effective anticancer therapy or changing treatment intent.
54.When does painful bone disease need more than irradiation?
External-beam radiotherapy can relieve pain from bone metastases, but the assessment must first distinguish uncomplicated pain from mechanical instability, impending fracture or neurological compression. These complications may require surgical or other urgent intervention alongside radiation. The irradiated site, prognosis, prior treatment and patient burden influence treatment selection. Pain response may take time, so analgesia and supportive measures continue while the local treatment effect develops rather than being withdrawn immediately after irradiation.
Apply it
A patient has severe weight-bearing pain from a femoral metastasis with concern for structural failure. Seek stability assessment before treating the problem as uncomplicated metastatic pain suitable for irradiation alone without orthopaedic input.
Common pitfall: Radiotherapy does not immediately restore bone strength. Assuming all painful metastases are uncomplicated can miss a preventable fracture or an urgent neurological threat.
55.Why should opioid constipation be anticipated?
Opioids reduce gastrointestinal motility and secretion, making constipation a predictable adverse effect during ongoing treatment. Unlike some early opioid effects, it often persists without reliable tolerance. Bowel assessment and preventive management should accompany opioid initiation when appropriate, with treatment adjusted to stool pattern and clinical context. New abdominal distension, vomiting or severe colicky pain requires evaluation for obstruction or another cause rather than simply escalating laxatives or attributing everything to the opioid.
Apply it
A patient begins regular opioid treatment for cancer pain and has normal bowel movements at baseline. Discuss a bowel plan at initiation and monitor response rather than waiting for several days of difficult stool passage.
Common pitfall: Avoiding needed analgesia is not the usual solution to predictable constipation. Conversely, reflex laxative escalation is inappropriate when symptoms raise concern for bowel obstruction.
56.How do goals-of-care discussions guide palliative treatment?
A goals-of-care discussion connects the patient’s understanding, values and priorities with realistic treatment benefits and burdens. Clinicians should clarify what matters most, explain uncertainty and check comprehension before recommending a plan. Symptom relief, time at home, function and longevity may carry different importance for different patients. Family involvement should support the patient’s preferences and decision-making capacity. The discussion is revisited when circumstances change rather than treated as a single completed administrative task.
Apply it
A patient values remaining at home and finds repeated travel exhausting. Discuss whether a proposed palliative intervention offers enough likely symptom benefit to justify its attendance burden, and check that the recommendation fits the patient’s stated priorities.
Common pitfall: Offering a technically feasible treatment without exploring its burden can produce care that conflicts with patient goals. Family preference should not automatically override a capable patient.
Trainingnot stated
57.How does a logbook demonstrate developing competence?
A useful logbook records dated clinical activities, procedures, case discussions and the level of participation, with appropriate supervisor certification. It distinguishes observation, assistance and performance rather than treating attendance as proof of independent competence. Reflection and feedback identify what improved and what still requires supervision. The curriculum expects evidence across clinical, technical and academic work, so a collection of undifferentiated procedure totals gives a weaker account than a documented progression in responsibility and reasoning.
Apply it
A trainee has observed several brachytherapy insertions but has not performed one under supervision. Record the observations accurately, identify the next supervised learning task and seek feedback instead of signing off independent procedural competence.
Common pitfall: A high case count can conceal passive participation or repeated errors. Retrospective, uncertified entries also weaken the credibility of an otherwise substantial training record.
Guidelines for Competency Based Training Programme in DNB–Radio Therapy
58.How should journal-club feedback change clinical learning?
Journal-club appraisal should connect the study question, design, outcomes, effect estimates and limitations to a clinical decision. Compare the trial population, intervention, comparator and outcomes with the intended clinical use. Baseline risk changes absolute benefit even when relative effects are similar, and a confidence interval describes uncertainty around the estimate. A small P value alone establishes neither an important benefit nor applicability. Formative feedback should identify a specific skill to practise, such as explaining absolute benefit or assessing differences in eligibility, adherence and available resources.
Apply it
After presenting a randomized trial, a trainee cannot explain whether the participants resemble local patients. Use feedback to set a focused task comparing eligibility, baseline risk and treatment resources before the next journal-club presentation.
Common pitfall: Repeating the abstract’s conclusion is not critical appraisal. A confidence interval spanning both important benefit and little benefit leaves consequential uncertainty; a large P value does not prove equivalence or absence of effect.
Guidelines for Competency Based Training Programme in DNB–Radio Therapy · Chapter 15: Interpreting results and drawing conclusions | Cochrane
Administrationnot stated
59.What must service planning include beyond purchasing equipment?
A radiotherapy service requires infrastructure, qualified staff, dosimetry, planning and verification systems, maintenance and quality management. Acceptance testing checks the installed equipment against agreed specifications; commissioning establishes measured local performance and treatment-planning data. End-to-end validation tests the connected clinical workflow, while staff training establishes operational readiness. Applicable AERB regulatory consent or approval is a separate prerequisite for authorized clinical operation. Technical commissioning and local readiness do not themselves confer regulatory permission. Continuing QA must then maintain performance after clinical introduction.
Apply it
A new accelerator has passed acceptance testing and technical commissioning, but workflow validation, staff preparation or applicable AERB authorization remains outstanding. Identify each unmet requirement separately and complete it before clinical operation rather than treating the commissioning report as permission to open.
Common pitfall: Vendor acceptance, technical commissioning, regulatory authorization and ongoing QA answer different questions. None alone demonstrates that the entire service is ready; the curriculum’s regulatory requirement does not establish current application steps or statutory deadlines.
Guidelines for Competency Based Training Programme in DNB–Radio Therapy · Clinical Training of Medical Physicists Specializing in Radiation Oncology
60.How do layered quality checks prevent treatment errors?
Radiotherapy quality management combines defined responsibilities, validated processes, independent checks and review of deviations across the treatment pathway. Different checks detect different failure modes: machine quality control does not establish correct patient selection, contouring or prescription transfer. Near misses reveal weaknesses before harm occurs and should lead to proportionate process review. Effective administration ensures that corrective actions have an owner and are evaluated, rather than treating a completed incident form as proof that the problem is solved.
Apply it
A prescription-transfer error is detected before the first fraction. Correct the individual record, then examine how the discrepancy arose and whether an independent check or workflow change can prevent recurrence in other patient records.
Common pitfall: Blaming one operator can leave the underlying process unchanged. Conversely, a passed machine test cannot validate every patient-specific planning, communication and treatment-delivery step.
Clinical Training of Medical Physicists Specializing in Radiation Oncology · Guidelines for Competency Based Training Programme in DNB–Radio Therapy
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Connect dose physics to clinical consequences: build-up, bolus, inverse-square behaviour, source decay and the assumptions behind biological dose comparisons.
- Explain each planning decision through biological target extent, positional uncertainty, spatial dose distribution and organ-specific risk.
- Practise cervical brachytherapy, breast adjuvant decisions, lung treatment selection, glioblastoma management and current HPV-associated oropharyngeal classification.
- Recognize treatment complications through discriminating cues, including vesicant injury, cumulative cardiotoxicity, immune inflammation and neurological compression.
- Interpret absolute benefit, censoring and study applicability before translating evidence into a treatment recommendation.
- Include prevention, palliation, supervised competence and departmental quality systems in revision across the complete official curriculum.
A practical preparation plan
1. Map the complete curriculum
Create a revision map using all eight official domains. Mark these 60 concepts as selected examples, then add omitted tumour sites, anatomy, pathology, procedures and emergencies from the full curriculum.
2. Build a calculation notebook
Work inverse-square, decay, BED, EQD2 and absolute-benefit exercises by hand. Write units, assumptions and the clinical limitation beneath every numerical result.
3. Rehearse structured short notes
Turn each concept into a concise written answer containing the principle, indications, decision criteria, technique or management, toxicity and relevant uncertainty. Practise timed papers using the applicable bulletin’s format.
4. Discuss complete clinical cases
For each major tumour site, present diagnosis, staging version, intent, modality sequence, target rationale, organ risks and follow-up. Defend one plausible alternative and explain why it is less suitable.
5. Use the drills diagnostically
Complete the 20 MCQs, explain every alternative aloud and classify errors as knowledge, calculation or interpretation problems. Revisit the matching concepts and use flashcards for spaced active recall.
6. Link revision to supervised practice
Review plans, images and procedures with supervisors. Update the logbook accurately, request feedback on weak competencies and rehearse clinical explanation, counselling and quality-assurance decisions for practical discussion.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- NBEMS Curriculum Index
- Guidelines for Competency Based Training Programme in DNB–Radio Therapy
- DNB Final Examination June 2026 Information Bulletin
- Radiation Oncology Physics: A Handbook for Teachers and Students
- Radiation Biology: A Handbook for Teachers and Students
- Management of Cervical Cancer: Strategies for Limited-resource Centres
- Clinical Training of Medical Physicists Specializing in Radiation Oncology
- Planning a Clinical PET Centre
- Cervical Cancer Treatment (PDQ), Health Professional Version
- Breast Cancer Treatment (PDQ), Health Professional Version
- Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
- Central Nervous System Tumors Treatment (PDQ), Health Professional Version
- Rectal Cancer Treatment (PDQ), Health Professional Version
- Oropharyngeal Cancer Treatment (PDQ), Health Professional Version
- Doxorubicin Hydrochloride Injection: Prescribing Information
- Organ-Related Inflammation and Immunotherapy
- Human Papillomavirus Vaccines
- Cancer Pain (PDQ), Health Professional Version
- Palliative Care in Cancer
- Brachytherapy to Treat Cancer
- Human Papillomavirus Testing in Head and Neck Carcinomas
- CAP Protocol for HPV-Associated Oropharyngeal Carcinoma Resection, Version 1.1.0.0
- New AJCC Staging System Protocols for Salivary Glands and Oropharynx Are Live
- KEYTRUDA (Pembrolizumab): Prescribing Information
- hpv-head-neck-update-summary-recommendations.pdf
- Chapter 15: Interpreting results and drawing conclusions | Cochrane
- download
- The value of cancer data
- Recommendations | Spinal metastases and metastatic spinal cord compression | Guidance | NICE
- ctcae-v403.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.